

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 18, 2025 (the “**Prospectus**”) issued by InSilico Medicine Cayman TopCo (英矽智能) (the “**Company**”).


This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act, or in the United States to qualified institutional buyers in reliance on Rule 144A or any other available exemption from the registration requirements under the U.S. Securities Act..

In connection with the Global Offering, Morgan Stanley Asia Limited, as the stabilizing manager (the “**Stabilizing Manager**”) (or its affiliates or any person acting for it), on behalf of the Underwriters, to the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing action is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that no stabilizing action can be taken to support the price of the Shares for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on Thursday, January 22, 2026, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering : 94,690,500 Offer Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares : 9,469,500 Offer Shares
Number of International Offer Shares : 85,221,000 Offer Shares (subject to reallocation and the Over-allotment Option)
Offer Price : HK\$24.05 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars, subject to refund)
Nominal Value : US\$0.0000005 per Offer Share
Stock Code : 3696

Joint Sponsors

Morgan Stanley

CICC

GF Securities

Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

Morgan Stanley

CICC

GF Securities

BNP Paribas

Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager

SINOLINK(HK)

Joint Bookrunner and Joint Lead Manager

BOCI

InSilico Medicine Cayman TopCo / 英矽智能

ANNOUNCEMENT OF ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 18, 2025 (the “**Prospectus**”) issued by InSilico Medicine Cayman TopCo (the “**Company**”).*

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded and should exercise extreme caution when dealing in the Shares.

SUMMARY

Company information

Stock code	3696
Stock short name	INSILICO
Dealings commencement date	December 30, 2025*

**see note at the end of the announcement*

Price Information

Offer Price	HK\$24.05
-------------	-----------

Offer Shares and Share Capital*

Number of Offer Shares	94,690,500
Number of Offer Shares in Hong Kong Public Offering	9,469,500
Number of Offer Shares in International Offering	85,221,000
Number of issued Shares upon Listing (before any exercise of the Over-allotment Option)	557,418,500

Over-allocation

No. of Offer Shares over-allocated	14,203,500
------------------------------------	------------

Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through the stock borrowing arrangement or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange’s website.

Proceeds	
Gross proceeds (Note)	HK\$2,277.3 million
Less: Estimated listing expenses payable based on Offer Price	HK\$251.5 million
Net proceeds	HK\$2,025.8 million

Note: Gross proceeds refers to the amount to which the Company is entitled to receive, without taking into account the Over-allotment Option. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus. In the event that the Over-allotment Option is exercised, the Company will adjust the allocation of the net proceeds on a pro rata basis.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	221,926
No. of successful applications	17,658
Subscription level	1,427.37 times
Claw-back triggered	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	9,469,500
Final no. of Offer Shares under the Hong Kong Public Offering	9,469,500
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	Approximately 10%

Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to <http://www.hkeipo.hk/IPOResult> to perform a search by identification number or <http://www.hkeipo.hk/IPOResult> for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	216
Subscription Level	26.27 times
No. of Offer Shares initially available under the International Offering	85,221,000
Final no. of Offer Shares under the International Offering	85,221,000
% of Offer Shares under the International Offering to the Global Offering	Approximately 90%

The Directors confirm that, to the best of their knowledge, information and belief, save for (a) consent under paragraph 1C of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) granted by the Stock Exchange and (b) consent under Chapter 4.15 of the Guide for New Listing Applicants to permit the Company to, among other things, allocate further Shares in the International Offering to (x) certain existing Shareholders and/or their respective close associates; and (y) Cornerstone Investors (including those who is a close associate of an existing Shareholder) and/or their respective close associates, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investors

<i>Investor ⁽¹⁾</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽²⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽²⁾</i>	<i>Existing shareholders or their close associates</i>
Lilly	1,617,500	1.71%	0.29%	No
Tencent ⁽³⁾	1,617,500	1.71%	0.29%	No
Oaktree	4,853,000	5.13%	0.87%	No
Schroders ⁽³⁾	4,853,000	5.13%	0.87%	No

<i>Investor ⁽¹⁾</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽²⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽²⁾</i>	<i>Existing shareholders or their close associates</i>
TAIBAI INVESTMENTS PTE. LTD. (“ Taibai Investments ”) ⁽³⁾⁽⁵⁾	4,853,000	5.13%	0.87%	close associate of an existing shareholder
UBS Asset Management (Singapore) Ltd. (“ UBS AM Singapore ”) ⁽³⁾⁽⁴⁾	4,853,000	5.13%	0.87%	No
China AMC ⁽³⁾	1,617,500	1.71%	0.29%	No
Pacific Asset Management Co., Ltd. (“ Pacific Asset Management ”) ⁽³⁾	1,617,500	1.71%	0.29%	No
E Fund Management ⁽³⁾⁽⁴⁾	1,294,000	1.37%	0.23%	No
Fullgoal HK ⁽³⁾	757,000	0.80%	0.14%	No
Fullgoal Fund ⁽³⁾	860,500	0.91%	0.15%	No
Harvest ⁽³⁾	1,617,500	1.71%	0.29%	No
Taikang Life ⁽³⁾	1,617,500	1.71%	0.29%	No
RTW ⁽³⁾	1,294,000	1.37%	0.23%	No
Emerging Markets Healthcare Partners LLC (“ EMHCP ”) ⁽³⁾	647,000	0.68%	0.12%	No
Infini ⁽³⁾	3,235,000	3.42%	0.58%	No
Total	37,204,500	39.29%	6.67%	

Notes:

1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.
2. Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans.

<i>Investor ⁽¹⁾</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽²⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽²⁾</i>	<i>Existing shareholders or their close associates</i>
3.	<i>In addition to the Offer Shares subscribed for as Cornerstone Investors, Tencent, Schroders, Taibai Investments, UBS AM Singapore, China AMC, Pacific Asset Management, E Fund Management, Fullgoal HK and Fullgoal Fund, Harvest, Taikang Life, RTW, EMHCP, Infini and/or their respective close associates, where applicable, were allocated further Offer Shares as placees in the International Offering. Please refer to the section headed "Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained" in this announcement for details. Only the Offer Shares subscribed for as Cornerstone Investors are subject to lock-up as indicated below. For details, please refer to the section headed "Lock-up Undertakings – Cornerstone Investors" in this announcement.</i>			
4.	<i>E Fund Management is a connected client of GF Securities (Hong Kong) Brokerage Limited and UBS AM Singapore is a connected client of UBS AG Singapore Branch. For details of consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients as Cornerstone Investors, please refer to the section headed "Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained" in this announcement.</i>			
5.	<i>Taibai Investments is a close associate of the Company's existing Shareholder, namely Palace Investments Pte. Ltd. which holds approximately 5.41% of the total issued share capital of the Company immediately prior to the Global Offering. For details of consent under paragraph 1C(2) of Appendix F1 and Chapter 4.15 of the Guide for New Listing Applicants for allocation Offer Shares to a close associate of an existing shareholder as Cornerstone Investor, please refer to the section headed "Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained" in this announcement.</i>			

Allottees with Waivers/Consents Obtained

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽¹⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽¹⁾</i>	<i>Relationship</i>
<i>Allottee with consent under Paragraph 1C(2) of Appendix F1 to the Listing Rules and Chapter 4.15 of the Guide for New Listing Applicants – Allocation of Offer Shares to a close associate of an existing shareholder as Cornerstone Investor ⁽²⁾</i>				
Taibai Investments	4,853,000	5.13%	0.87%	A Cornerstone Investor and a close associate of an existing Shareholder
<p><i>Notes:</i></p> <ol style="list-style-type: none"> <i>Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans.</i> <i>The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, consent under Paragraph 1C(2) of Appendix F1 to the Listing Rules and Chapter 4.15 of the Guide for New Listing Applicants for the allocation of Offer Shares to Taibai Investments as Cornerstone Investor. For details of the grounds and conditions for such consent, see the section headed “Waivers and Exemptions” in the Prospectus and the section headed “Others/Additional Information” in this announcement.</i> 				

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽¹⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽¹⁾</i>	<i>Relationship</i>
<i>Allottees with consent under paragraph 1C(2) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations of further Offer Shares to (i) Cornerstone Investors and/or their close associates and (ii) existing Shareholders and/or their close associates as placees ⁽²⁾</i>				
Tencent	800,000	0.84%	0.14%	A Cornerstone Investor
Schroders	2,425,000	2.56%	0.44%	A Cornerstone Investor
Taibai Investments	2,425,000	2.56%	0.44%	A Cornerstone Investor
UBS AM Singapore ⁽³⁾⁽⁴⁾	2,445,000	2.58%	0.44%	A Cornerstone Investor
China AMC	800,000	0.84%	0.14%	A Cornerstone Investor
Pacific Asset Management	575,000	0.61%	0.10%	A Cornerstone Investor
CPIC Investment Management HK Limited (“CPIC”)	225,000	0.24%	0.04%	Close associate of Pacific Asset Management, a Cornerstone Investor
E Fund Management ⁽⁴⁾	645,000	0.68%	0.12%	A Cornerstone Investor
Fullgoal HK	375,500	0.40%	0.07%	A Cornerstone Investor
Fullgoal Fund	424,500	0.45%	0.08%	A Cornerstone Investor
Harvest	800,000	0.84%	0.14%	A Cornerstone Investor
Taikang Life	800,000	0.84%	0.14%	A Cornerstone Investor
RTW	645,000	0.68%	0.12%	A Cornerstone Investor

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽¹⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽¹⁾</i>	<i>Relationship</i>
Worldwide Healthcare Partners LLC (“WHP”)	320,000	0.34%	0.06%	Close associate of EMHCP, a Cornerstone Investor
Infini	1,600,000	1.69%	0.29%	A Cornerstone Investor
SMALLCAP World Fund, Inc. (“SMALLCAP”) ⁽⁵⁾	3,269,500	3.45%	0.59%	An existing Shareholder
Capital Group Asian Horizon Fund (LUX) (“ Capital Horizon Fund ”), Caisse de Prevoyance de Etat de Geneve CPEG Synergie Actions Pacifique (“ Pacifique Fund ”), Capital Group Future Generations Global Balanced Fund (LUX) (“ Capital Balance Fund ”) and Capital Group Future Generations Global Opportunities Fund (LUX) (“ Capital Opportunities Fund ”) ⁽⁶⁾	275,500	0.29%	0.05%	Close associates of SMALLCAP, an existing shareholder
Drug Development ⁽⁷⁾	971,000	1.03%	0.17%	A close associate of an existing shareholder
MIRAE ASSET SECURITIES CO., LTD (“ Mirae Asset Securities ”) ⁽⁸⁾	160,000	0.17%	0.03%	A close associate of existing shareholders
OrbiMed Asia Partners IV, L.P. (“ OAP IV ”) ⁽⁹⁾	65,000	0.07%	0.01%	An existing Shareholder

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽¹⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽¹⁾</i>	<i>Relationship</i>
-----------------	--------------------------------------	---	---	---------------------

Notes:

- 1. Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans.*
- 2. The number of Offer Shares allocated to the relevant investors listed in this subsection only represents the number of Offer Shares allocated to the investors as placees in the International Offering. For allocations of Offer Shares to the relevant investors as Cornerstone Investors, please refer to the section headed "Allotment Results Details – Cornerstone Investors" in this announcement. For details of the consent under Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations of further Offer Shares to Cornerstone investors and/or their close associates, please refer to the section headed "Others/ Additional Information" in this announcement.*
- 3. 2,425,000 Offer Shares are allocated to UBS AM Singapore as placee and 20,000 Offer Shares are allocated to UBS O'Connor, a team under UBS AM Singapore. Accordingly, UBS AM Singapore is allocated 2,445,000 Offer Shares as placee in aggregate.*
- 4. E Fund Management is a connected client of GF Securities (Hong Kong) Brokerage Limited and UBS AM Singapore is a connected client of UBS AG Singapore Branch. For details of the consent under paragraph 1C of Appendix F1 to the Listing Rules in relation to allocation of Share to connected clients as placees, please refer to the section headed "Others/ Additional Information" in this announcement.*

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽¹⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽¹⁾</i>	<i>Relationship</i>
-----------------	--------------------------------------	---	---	---------------------

Notes:

5. *SMALLCAP is an existing Shareholder and held 13,568,160 Shares immediately prior to the Global Offering. Immediately upon completion of the Global Offering, together with the Offer Shares allocated, it will hold approximately 3.02% of the total issued share capital of the Company.*
6. *Each of Capital Horizon Fund, Pacifique Fund, Capital Balance Fund and Capital Opportunities Fund is a close associate of SMALLCAP, an existing shareholder which holds approximately 2.93% of the total issued share capital of the Company immediately prior to the Global Offering.*
7. *Drug Development is a close associate of Drug Discovery Consultants Limited, an existing shareholder which holds approximately 1.51% of the total issued share capital of the Company immediately prior to the Global Offering.*
8. *Mirae Asset Securities is a close associate of existing shareholders, namely Mirae Asset Growth 6, Mirae Asset New Economy, Mirae Asset Sage Fund I and Mirae Innovation Fund I (collectively, the "Mirae Entities"), which holds approximately 1.74% of the total issued share capital of the Company in aggregate immediately prior to the Global Offering.*
9. *OAP IV is an existing Shareholder and held 10,481,020 Shares immediately prior to the Global Offering. Immediately upon completion of the Global Offering, together with the Offer Shares allocated, it will hold approximately 1.89% of the total issued share capital of the Company.*

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽¹⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽¹⁾</i>	<i>Relationship</i>
<i>Allottees with consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients ⁽²⁾</i>				
UBS AM Singapore	4,853,000	5.13%	0.87%	Connected client as Cornerstone Investor
UBS AM Singapore	2,445,000	2.58%	0.44%	Connected client as placee
ICBC UBS Asset Management Co., (International) Ltd. ("ICBC UBS")	388,000	0.41%	0.07%	Connected client
E Fund Management	1,294,000	1.37%	0.23%	Connected client as Cornerstone Investor
E Fund Management	645,000	0.68%	0.12%	Connected client as placee
GF Global Capital Limited ("GFGC")	3,000	0.003%	0.0005%	Connected client
<i>Notes:</i> 1. Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans. 2. For details of the consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients, please refer to section headed "Others/Additional Information" in this announcement.				

Allottee who are customer(s) or client(s) / supplier(s) of the Company

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares ⁽¹⁾</i>	<i>% of the Company's total issued share capital immediately following completion of the Global Offering ⁽¹⁾</i>	<i>Relationship</i>
Lilly ⁽²⁾	1,617,500	1.71%	0.29%	Customer of the Company and a Cornerstone Investor

Note:

- Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans.*
- For further details of Lilly, please refer to the section headed "Cornerstone Investors" in the Prospectus.*

LOCK-UP UNDERTAKINGS

Cornerstone Investors

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾</i>	<i>Last day subject to the lock-up undertakings ⁽²⁾</i>
Lilly	1,617,500	0.29%	June 29, 2026
Tencent	1,617,500	0.29%	June 29, 2026
Oaktree	4,853,000	0.87%	June 29, 2026
Schroders	4,853,000	0.87%	June 29, 2026
Taibai Investments	4,853,000	0.87%	June 29, 2026
UBS AM Singapore	4,853,000	0.87%	June 29, 2026
China AMC	1,617,500	0.29%	June 29, 2026

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾</i>	<i>Last day subject to the lock-up undertakings ⁽²⁾</i>
Pacific Asset Management	1,617,500	0.29%	June 29, 2026
E Fund Management	1,294,000	0.23%	June 29, 2026
Fullgoal HK	757,000	0.14%	June 29, 2026
Fullgoal Fund	860,500	0.15%	June 29, 2026
Harvest	1,617,500	0.29%	June 29, 2026
Taikang Life	1,617,500	0.29%	June 29, 2026
RTW	1,294,000	0.23%	June 29, 2026
EMHCP	647,000	0.12%	June 29, 2026
Infini	3,235,000	0.58%	June 29, 2026
Total	37,204,500	6.67%	June 29, 2026

Notes:

- 1. Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans.*
- 2. In accordance with the relevant cornerstone investment agreements, the required lock-up ends on June 29, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date. For details, please refer to the section headed “Cornerstone Investors – Restrictions on the Cornerstone Investors” of the Prospectus.*

Existing Shareholders

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾</i>	<i>Last day subject to the lock-up undertakings ⁽²⁾</i>
DKV	2,850,260	0.51%	June 29, 2026
DKAIT	7,700,000	1.38%	June 29, 2026
A-level Capital	47,420	0.01%	June 29, 2026
BMH Capital	229,120	0.04%	June 29, 2026
Bridget Jane Holmewood	229,120	0.04%	June 29, 2026
Bruce Chou, RP	400,640	0.07%	June 29, 2026
BRLS	98,040	0.02%	June 29, 2026
William Gelpi	461,780	0.08%	June 29, 2026
Richard Redmond and Aileen Redmond	229,080	0.04%	June 29, 2026
RyanChow Super Fund	180,000	0.03%	June 29, 2026
STBS Consultants	135,380	0.02%	June 29, 2026
Synaro	2,565,900	0.46%	June 29, 2026
Ted M Routt	561,740	0.10%	June 29, 2026
WuXi	20,265,480	3.64%	June 29, 2026
Palace Investments	25,054,720	4.49%	June 29, 2026
Bold Capital II	13,139,040	2.36%	June 29, 2026
Bold Capital Select	2,748,060	0.49%	June 29, 2026
QVP VI	23,136,080	4.15%	June 29, 2026
QMD VI	622,560	0.11%	June 29, 2026
QVP VII	8,240,620	1.48%	June 29, 2026

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾</i>	<i>Last day subject to the lock-up undertakings ⁽²⁾</i>
SIF VII	75,940	0.01%	June 29, 2026
LAV Biosciences Fund V	9,283,880	1.67%	June 29, 2026
LAV Fund VI	4,192,400	0.75%	June 29, 2026
LAV Fund VI Opportunities	4,192,400	0.75%	June 29, 2026
Sinovation Fund IV	9,682,920	1.74%	June 29, 2026
SV China	2,096,200	0.38%	June 29, 2026
Tubus	7,187,680	1.29%	June 29, 2026
Michael Antonov Charitable Foundation	1,197,940	0.21%	June 29, 2026
Formic Ventures	1,397,460	0.25%	June 29, 2026
Baidu Ventures	1,204,940	0.22%	June 29, 2026
Longevity Vision Holding I LLC	5,989,740	1.07%	June 29, 2026
ERVC Healthcare IV	7,786,240	1.40%	June 29, 2026
ERVC Technology IV	7,786,240	1.40%	June 29, 2026
F-Prime Capital Fund VI	2,395,880	0.43%	June 29, 2026
Mesolite	46,383,400	8.32%	June 29, 2026
HSG Growth	3,493,680	0.63%	June 29, 2026
B Capital China III	6,987,340	1.25%	June 29, 2026
Deerfield Partners	3,959,700	0.71%	June 29, 2026
Deerfield Private Design Fund V	3,959,700	0.71%	June 29, 2026
Mirae Asset Growth 6	698,740	0.13%	June 29, 2026

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾</i>	<i>Last day subject to the lock-up undertakings ⁽²⁾</i>
Mirae Asset New Economy	4,891,140	0.88%	June 29, 2026
Mirae Asset Sage Fund I	1,048,120	0.19%	June 29, 2026
Mirae Innovation Fund I	1,397,460	0.25%	June 29, 2026
President	3,493,680	0.63%	June 29, 2026
LBC Sunshine Healthcare Fund II L.P.	3,493,680	0.63%	June 29, 2026
CYX Technology	10,481,020	1.88%	June 29, 2026
MSPR III	6,288,620	1.13%	June 29, 2026
GSUM VI	4,192,400	0.75%	June 29, 2026
OAP IV	10,481,020	1.88%	June 29, 2026
MS Sublime	4,192,400	0.75%	June 29, 2026
WS Investment (21A)	349,380	0.06%	June 29, 2026
Sage Partners	1,746,840	0.31%	June 29, 2026
Eight Roads Japan II	2,794,940	0.50%	June 29, 2026
Anchor	3,493,680	0.63%	June 29, 2026
Dream Team Ventures	3,493,680	0.63%	June 29, 2026
Fosun Industrial	10,481,020	1.88%	June 29, 2026
B Capital (China) I	10,224,840	1.83%	June 29, 2026
SMALLCAP	13,568,160	2.43%	June 29, 2026
Prosperity7	14,321,660	2.57%	June 29, 2026

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾</i>	<i>Last day subject to the lock-up undertakings ⁽²⁾</i>
BHR Investment Fund X	2,556,200	0.46%	June 29, 2026
Sino Biopharm	2,556,200	0.46%	June 29, 2026
WS Investment (22A)	102,280	0.02%	June 29, 2026
Value Partners Apollo	23,696,040	4.25%	June 29, 2026
Pudong ChuangLing	5,807,840	1.04%	June 29, 2026
Puxing Synergetic Fund	5,807,840	1.04%	June 29, 2026
Wuxi Xichuang	8,051,800	1.44%	June 29, 2026
Grand Leader	387,180	0.07%	June 29, 2026
Kawn Holdings RSC LTD	774,380	0.14%	June 29, 2026
Total	399,020,960	71.58%	

Notes:

- Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans.*
- Each of the above existing Shareholders has entered into a deed of lock-up undertaking in favor of the Company, the Joint Sponsors and the Overall Coordinators, pursuant to which at any time during the period commencing on the date of the Prospectus and ending on, and including the date falling six months from the Listing Date, directly or indirectly, dispose of or transfer any Shares held by it, subject to certain exceptions.*

Other Existing Shareholders

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing ⁽¹⁾</i>	<i>Last day subject to the lock-up undertakings ⁽²⁾</i>
Aleksandrs Zavoronkovs ⁽⁴⁾	42,583,500	7.64%	December 29, 2026
Employees and consultants ⁽⁴⁾	4,415,400	0.79%	December 29, 2026
Former employees and consultants ⁽⁵⁾	16,708,140	3.00%	June 29, 2026
Total	63,707,040	11.43%	

Notes:

3. *Assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans.*
4. *Each of the above existing Shareholders has entered into a deed of lock-up undertaking in favor of the Company, the Joint Sponsors and the Overall Coordinators, pursuant to which at any time during the period commencing on the date of the Prospectus and ending on, and including the date falling twelve months from the Listing Date, directly or indirectly, dispose of or transfer any Shares held by it, subject to certain exceptions.*
5. *Each of the former employees and consultants has entered into a deed of lock-up undertaking in favor of the Company, the Joint Sponsors and the Overall Coordinators, pursuant to which at any time during the period commencing on the date of the Prospectus and ending on, and including the date falling six months from the Listing Date, directly or indirectly, dispose of or transfer any Shares held by it, subject to certain exceptions.*

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised in full)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)
Top 1	7,298,000	8.56%	7.34%	7.71%	6.70%	7,298,000	1.31%	1.28%
Top 5	31,542,000	37.01%	31.72%	33.31%	28.97%	56,596,720	10.15%	9.90%
Top 10	46,329,500	54.36%	46.60%	48.93%	42.55%	84,952,380	15.24%	14.86%
Top 25	75,891,500	89.05%	76.33%	80.15%	69.69%	114,514,380	20.54%	20.03%

Note

* Ranking of placees is based on the number of Shares allotted to the placees.

SHAREHOLDERS CONCENTRATION ANALYSIS

Shareholders*	Number of Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised in full)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised in full)
Top 1	–	0.00%	0.00%	0.00%	0.00%	46,643,500	8.37%	8.16%
Top 5	7,278,000	8.54%	7.32%	7.69%	6.68%	181,130,860	32.49%	31.69%
Top 10	10,823,000	12.70%	10.89%	11.43%	9.94%	271,757,780	48.75%	47.54%
Top 25	19,317,000	22.67%	19.43%	20.40%	17.74%	427,119,420	76.62%	74.72%

Note

* Ranking of Shareholders is based on the number of Shares held by the Shareholder immediately upon completion of the Global Offering.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

BASIS OF ALLOTMENT FOR PRESS ANNOUNCEMENT

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
POOL A			
500	87,909	880 out of 87,909 applicants to receive 500 shares	1.00%
1,000	13,678	204 out of 13,678 applicants to receive 500 shares	0.75%
1,500	7,716	145 out of 7,716 applicants to receive 500 shares	0.63%
2,000	20,126	444 out of 20,126 applicants to receive 500 shares	0.55%
2,500	5,669	142 out of 5,669 applicants to receive 500 shares	0.50%
3,000	2,419	68 out of 2,419 applicants to receive 500 shares	0.47%
3,500	1,649	50 out of 1,649 applicants to receive 500 shares	0.43%
4,000	4,063	133 out of 4,063 applicants to receive 500 shares	0.41%
4,500	1,780	63 out of 1,780 applicants to receive 500 shares	0.39%
5,000	8,392	312 out of 8,392 applicants to receive 500 shares	0.37%
6,000	2,155	89 out of 2,155 applicants to receive 500 shares	0.34%
7,000	1,649	75 out of 1,649 applicants to receive 500 shares	0.32%
8,000	1,878	92 out of 1,878 applicants to receive 500 shares	0.31%
9,000	1,428	75 out of 1,428 applicants to receive 500 shares	0.29%
10,000	5,920	327 out of 5,920 applicants to receive 500 shares	0.28%

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
15,000	4,146	288 out of 4,146 applicants to receive 500 shares	0.23%
20,000	3,746	307 out of 3,746 applicants to receive 500 shares	0.20%
25,000	2,759	257 out of 2,759 applicants to receive 500 shares	0.19%
30,000	2,175	225 out of 2,175 applicants to receive 500 shares	0.17%
35,000	1,593	180 out of 1,593 applicants to receive 500 shares	0.16%
40,000	1,705	208 out of 1,705 applicants to receive 500 shares	0.15%
45,000	1,521	198 out of 1,521 applicants to receive 500 shares	0.14%
50,000	2,821	390 out of 2,821 applicants to receive 500 shares	0.14%
60,000	2,002	307 out of 2,002 applicants to receive 500 shares	0.13%
70,000	1,374	230 out of 1,374 applicants to receive 500 shares	0.12%
80,000	1,409	255 out of 1,409 applicants to receive 500 shares	0.11%
90,000	1,260	243 out of 1,260 applicants to receive 500 shares	0.11%
100,000	7,176	1,470 out of 7,176 applicants to receive 500 shares	0.10%
200,000	5,963	1,813 out of 5,963 applicants to receive 500 shares	0.08%
Total	206,081	Total number of Pool A successful applicants: 9,470	

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
POOL B			
300,000	7,483	2,470 out of 7,483 applicants to receive 500 shares	0.06%
400,000	1,782	748 out of 1,782 applicants to receive 500 shares	0.05%
500,000	1,300	658 out of 1,300 applicants to receive 500 shares	0.05%
600,000	888	523 out of 888 applicants to receive 500 shares	0.05%
700,000	688	461 out of 688 applicants to receive 500 shares	0.05%
800,000	536	402 out of 536 applicants to receive 500 shares	0.05%
900,000	456	377 out of 456 applicants to receive 500 shares	0.05%
1,000,000	1,663	1,500 out of 1,663 applicants to receive 500 shares	0.05%
2,000,000	521	500 shares plus 318 out of 521 applicants to receive an additional 500 shares	0.04%
3,000,000	243	1,000 shares plus 63 out of 243 applicants to receive an additional 500 shares	0.04%
4,734,500	285	1,500 shares plus 87 out of 285 applicants to receive an additional 500 shares	0.03%
Total	15,845	Total number of Pool B successful applicants: 8,188	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

OTHERS/ADDITIONAL INFORMATION

Consent under paragraph 1C(2) of Appendix F1 and Chapter 4.15 of the Guide for New Listing Applicants – Allocation of Offer Shares to a close associate of an existing shareholder as cornerstone investor

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, consent under Paragraph 1C(2) of Appendix F1 to the Listing Rules and Chapter 4.15 of the Guide for New Listing Applicants for the allocation of Offer Shares to Taibai Investments as Cornerstone Investor under the Global Offering, subject to the conditions below:

- (a) the final offer size of the Global Offering, excluding any over-allocation, has a total value of at least HK\$1 billion;
- (b) securities allocated to all existing shareholders and their close associates (whether as cornerstone investors and/or as placees) as permitted under this exemption do not exceed 30% of the total number of securities offered;
- (c) the Company does not have any controlling shareholder, and each Director and chief executive of the Company confirm that no securities have been allocated to them or their respective close associates under the exemption; (together, the “**Size-based Exemption Conditions**”) and
- (d) the allocation to Taibai Investments will not affect the Company’s ability to satisfy the public float requirement under Rule 8.08(1) of the Listing Rules and details of the allocation will be disclosed in the Prospectus and the allotment results announcement.

Consent under paragraph 1C(2) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants – Allocations of further Offer Shares to (i) Cornerstone Investors and/or their close associates and (ii) existing Shareholders and/or their close associates as placees (together, the “Size-based Exemption Participants”)

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, consent under paragraph 1C(2) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations of further Offer Shares to the Size-based Exemption Participants, subject to the conditions below:

- (a) the Size-based Exemption Conditions; and
- (b) the allocation to the Size-based Exemption Participants will not affect the Company’s ability to satisfy the public float requirement under Rule 8.08(1) of the Listing Rules and details of the allocation will be disclosed in the allotment results announcement.

Such allocations of Offer Shares are in compliance with all the conditions under the consent granted by the Stock Exchange. For details of the allocations of Offer Shares to (i) Taibai Investments and (ii) the Size-based Exemption Participants, please refer to the section headed “Allotment Results Details – International Offering – Allotees with Waivers/Consents Obtained” in this announcement.

Consent under paragraph 1C(1) of Appendix F1 – Allocation of Shares to connected clients as cornerstone investors and placees

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, consent under paragraph 1C of the Placing Guidelines to permit allocation to connected clients pursuant to the Placing Guidelines. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consents granted by the Stock Exchange. Details of the placement to connected clients (including the cornerstone tranche and placing tranche) are set out below.

Connected Distributor	Connected Client	Relationship with the Connected Distributor(s)	Whether the Connected Client(s) will hold the beneficial interests of the Offer Shares on a non-discretionary basis or discretionary basis for independent third parties	Number of Offer Shares to be allocated to the connected client	Approximately percentage of total number of Offer Shares (assuming Over-allotment Option is not exercised)	Shareholding upon completion of the Global Offering (assuming Over-allotment Option is Name of existing not exercised)
UBS AG Singapore Branch (“UBS AG SG”)	UBS AM Singapore ⁽¹⁾	UBS AM Singapore is a member of the same group of companies as UBS AG SG	Discretionary basis	4,853,000 (as Cornerstone Investor)	5.13%	0.87%
				2,445,000 (as placee)	2.58%	0.44%
	ICBC UBS Asset Management Co., (International) Ltd. (“ICBC UBS”) ⁽²⁾	ICBC UBS is a member of the same group of companies as UBS AG SG	Discretionary basis	388,000	0.41%	0.07%
GF Securities (Hong Kong) Brokerage Limited (“GF Securities (Hong Kong) Brokerage”)	E Fund Management ⁽³⁾	E Fund Management is a member of the same group with GF Securities (Hong Kong) Brokerage	Discretionary basis	1,294,000 (as Cornerstone Investor)	1.37%	0.23%
				645,000 (as placee)	0.68%	0.12%
	GF Global Capital Limited (“GFGC”) ⁽⁴⁾	GFGC is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Non-discretionary	3,000	0.003%	0.0005%

Notes:

1. UBS AM Singapore subscribed for the Offer Shares both as a Cornerstone Investor and as a placee. UBS AM Singapore (as the delegate of the investment manager for and on behalf of certain investors) (the “**Ultimate Clients**”) will hold the Offer Shares for and on behalf of its Ultimate Clients on discretionary basis under the International Offering. 2,425,000 Offer Shares are allocated to UBS AM Singapore as placee and 20,000 Offer Shares are allocated to UBS O’Connor, a team under UBS AM Singapore. Accordingly, UBS AM Singapore is allocated 2,445,000 Offer Shares as placee in aggregate. To the best knowledge of UBS AM Singapore, and after making all reasonable enquiries, (i) each of their Ultimate Clients is an independent third party of the Company, its subsidiaries and substantial shareholders, UBS AM Singapore, UBS AG SG and the companies which are members of the same group of UBS AG SG; and (ii) UBS AM Singapore is not a collective investment scheme which is not authorized by the SFC nor is expected to hold the Offer Shares on behalf of such scheme.
2. ICBC UBS acting as an investment manager will hold the Offer Shares for and on behalf of independent third party on a discretionary basis. To the best knowledge of ICBC UBS after due enquiry, each of the underlying clients of ICBC UBS is an independent third party of the Company, its subsidiaries, its substantial shareholders, UBS AG SG and the companies which are members of the same group of UBS AG SG.
3. E Fund Management subscribed for the Offer Shares both as a Cornerstone Investor and as a placee. E Fund Management will hold the Offer Shares for and on behalf of their underlying clients (the “**Ultimate Clients**”) on discretionary basis under the International Offering. To the best knowledge of E Fund Management and after making all reasonable enquiries, each of the Ultimate Clients is independent from the Company, its subsidiaries, its substantial shareholders, GF Securities (Hong Kong) Brokerage, E Fund Management and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage.
4. GFGC entered into a series of cross border delta-one OTC swap transactions (the “**OTC Swaps**”) with the ultimate client (the “**GFGC Ultimate Clients**”), pursuant to which GFGC will hold the Offer Shares on a non-discretionary basis to hedge the OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the GFGC Ultimate Clients, and the OTC Swaps are fully funded by the GFGC Ultimate Clients. To the best knowledge of GFGC, each of the GFGC Ultimate Clients and its respective investment manager is an independent third party of the Company, its subsidiaries, its substantial shareholders, GFGC, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of GF Securities (Hong Kong) Brokerage and no proprietary money is used for the placing.

GFGC is to invest on a non-discretionary basis on behalf of the following GF Ultimate Clients: (i) Juming Medical Industry Private Securities Investment Fund (聚鳴醫療產業私募證券投資基金) whose UBO holding 30% or more interest is Liu Xiaolong (劉曉龍); and (ii) Minghong Multi-Strategy Hedge No. 1 Private Securities Investment Fund (明宏多策略對沖1號私募證券投資基金). No ultimate beneficial owner holds 30% or more interest therein.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company’s Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.*

The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act, or in the United States to qualified institutional buyers in reliance on Rule 144A or any other available exemption from the registration requirements under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated December 18, 2025 issued by InSilico Medicine Cayman TopCo for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Joint Sponsors and the Sponsor-Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, December 30, 2025).*

PUBLIC FLOAT

Immediately after the completion of the Global Offering (assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans), 510,299,600 Shares, representing approximately 91.55% of the total issued share capital of the Company, are counted towards the public float, which is higher than the prescribed percentage of Shares required to be held in public hands of 15% under Rule 8.08(1) of the Listing Rules calculated based on the Offer Price of HK\$24.05 per Share, thereby satisfying Rule 8.08(1) of the Listing Rules. Based on the Offer Price of HK\$24.05 per Share, the free float of our Company is approximately 10.31% and with a market value at the time of the Listing of approximately HK\$1,382.5 million (assuming (i) the Over-allotment Option is not exercised; and (ii) without taking into account any Shares to be issued pursuant to the Pre-IPO Equity Incentive Plans and the Post-IPO Equity Incentive Plans) and therefore the Company satisfies the free float requirement under Rule 8.08A of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, December 30, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the Shares on the basis of publicly available allocation details prior to the receipt of Share certificates or prior to the Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, December 30, 2025 (Hong Kong time), it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, December 30, 2025 (Hong Kong time). The Shares will be traded in board lots of 500 Shares each, and the stock code of the Shares will be 3696.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs
Chairman, Executive Director and CEO

Hong Kong, December 29, 2025

Directors and proposed directors of the Company named in the application to which this announcement relates are: (i) Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; (ii) Mr. Chuen Yan Leung, Ph.D., Mr. Kan Chen, Ph.D. and Mr. Long Shi as non-executive directors; and (iii) Ms. Denitsa Milanova, Ph.D., Mr. Jingsong Wang, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.